公开(公告)号：WO2020072098A1

公开(公告)日：2020-04-09

申请号：PCT/US2019/027754

申请日：2019-04-16

Applicant: TACSENSE, INC.

Inventor： PAN, Tingrui ,  BAZOR, Benjamin Arthur ,  ZHANG, Zhichao

IPC: A61B5/00 ,  A61B5/0408

Abstract: A foot-based wearable system disposed proximate to the dorsalis pedis artery can detect cardiac and muscular activities. Utilizing flexible iontronic sensing (FITS) technology, a sensing array detects both cardiovascular functions, such as heart rate, ECG, and respiration and motion artifact signals with a spatial reference to muscular activities based on the orientation of the array. Individual tendon responses are analyzed and correlated to different pedal gestures, from which multi-channel signals can be used to distinguish different activities. Wearable articles of the invention include a platform to simultaneously analyze both vital signals and body activities from the cardiac waveforms and muscular responses in a natural and unnoticeable fashion. The data-collecting wearable system provides a means to assess personalized health and daily activities on a continuous basis.

公开(公告)号：WO2020041631A1

公开(公告)日：2020-02-27

申请号：PCT/US2019/047775

申请日：2019-08-22

Applicant: AVALYN PHARMA INC.

Inventor： SURBER, Mark William ,  PHAM, Stephen

IPC: C07D209/34 ,  C07D403/12 ,  A61K9/00

Abstract: Disclosed herein are formulations of nintedanib and salts thereof, indolinone derivative compounds and salts thereof for aerosolization and use of such formulations for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. Formulations and delivery options described herein allow for efficacious local delivery of nintedanib or a indolinone derivative compound or salt thereof. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that benefit by reformulation and inhalation administration.

公开(公告)号：WO2018222781A3

公开(公告)日：2018-12-06

申请号：PCT/US2018/035227

申请日：2018-05-30

Applicant: EMERSON, Paul G.

Inventor： EMERSON, Paul G.

IPC: A61K38/22 ,  A61K39/395 ,  A61K45/00 ,  C07D311/34 ,  C07D311/36

Abstract: The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The methods of the invention include administration to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.

公开(公告)号：WO2013010041A1

公开(公告)日：2013-01-17

申请号：PCT/US2012/046559

申请日：2012-07-12

Applicant: CARDEAS PHARMA INC. ,  MONTGOMERY, Alan Bruce

Inventor： MONTGOMERY, Alan Bruce

IPC: A61K9/00 ,  A61K31/665 ,  A61K31/7036

CPC classification number: A61K31/7036 ,  A61K9/0078 ,  A61K31/665 ,  A61K2300/00

Abstract: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract translation: 本发明是与呼吸机相关性肺炎（VAP）和呼吸机相关气管（VAT）支气管炎相关的抗生素组合物，基于呼吸机的系统和方法。 磷霉素和氨基糖苷类，优选阿米卡星的抗生素组合通过呼吸机气道内的直列雾化器施用。 加湿条件产生改善的气雾剂以处理VAP和增值税。

公开(公告)号：WO2018222781A2

公开(公告)日：2018-12-06

申请号：PCT/US2018/035227

申请日：2018-05-30

Applicant: EMERSON, Paul G.

Inventor： EMERSON, Paul G.

IPC: A61K31/353 ,  A61K31/381

Abstract: The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The methods of the invention include administration to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.

公开(公告)号：WO2010060114A1

公开(公告)日：2010-05-27

申请号：PCT/US2009/065826

申请日：2009-11-24

Applicant: ACROMETRIX ,  SCHOENBRUNNER, Erhard, R. ,  BEHRENS, Sven-Erik

Inventor： SCHOENBRUNNER, Erhard, R. ,  BEHRENS, Sven-Erik

IPC: C12N7/00 ,  C12N7/02 ,  C12N5/10

CPC classification number: C12N7/00 ,  C07H21/02 ,  C12N15/86 ,  C12N2770/24211 ,  C12N2770/24222 ,  C12N2770/24311 ,  C12N2770/24322

Abstract: The construction of a chimeric Pestivirus by the identification of selected regions in the 3'NTR of the viral RNA genome is described where additional RNA sequences can be stably inserted. These sequence insertions in the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3'NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.

Abstract translation: 描述通过鉴定病毒RNA基因组的3'NTR中的选定区域来构建嵌合瘟病毒，其中可以稳定地插入另外的RNA序列。 病毒RNA基因组中的这些序列插入在复制中是稳定的并且能够形成感染性的RNA酶抗性病毒颗粒。 这种具有3'NTR插入的嵌合瘟病毒可以用作RNA靶标的分析测定中的质量控制材料，包括外部，内部对照，PCR和NAT核酸测定中的定量标准。

公开(公告)号：WO2006089294A2

公开(公告)日：2006-08-24

申请号：PCT/US2006/006227

申请日：2006-02-21

Applicant: ORIGEN THERAPEUTICS, INC. ,  ZHU, Lei ,  ZHOU, Wen ,  ETCHES, Robert, J.

Inventor： ZHU, Lei ,  ZHOU, Wen ,  ETCHES, Robert, J.

IPC: A01K67/027 ,  C07K16/44

CPC classification number: A01K67/0275 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2227/30 ,  A01K2267/01 ,  C07K16/02 ,  C07K2317/11 ,  C07K2317/732 ,  C07K2317/77 ,  C12N15/8509

Abstract: Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of trangene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems.

Abstract translation: 编码外源抗体的转基因稳定整合到供体细胞中，并存在于嵌合鸟的体细胞组织中。 转基因编码外源抗体，优选在输卵管中表达以在卵中收集。 通过相应地选择转基因的内容来提供组织特异性。 其基因组由转基因衍生的外源抗体编码DNA组成的鸟表达具有理想化学性质的外源性抗体，与来源于细菌表达系统的抗体相比具有增加的治疗效用。

公开(公告)号：WO2022066802A8

公开(公告)日：2022-03-31

申请号：PCT/US2021/051598

申请日：2021-09-22

Applicant: AVALYN PHARMA INC.

Inventor： SURBER, Mark William ,  PHAM, Stephen

IPC: A61M11/00 ,  A61M16/00 ,  A61M15/00 ,  A61K9/00 ,  A61M11/001 ,  A61M11/005 ,  A61M15/0015 ,  A61M15/0018 ,  A61M15/0085 ,  A61M15/0086 ,  A61M2016/0024 ,  A61M2209/06

Abstract: Disclosed herein is a nebulizer comprising of a medicine cup reservoir containing an aqueous pirfenidone solution a medicine cup reservoir cap, an aerosol generator, an aerosol mixing chamber to which freshly generated aerosol resides until inhaled, a one-way inhalation valve, a mouthpiece and a one-way exhalation valve. The invention allows atmospheric pressure to be maintained inside the medicine cup reservoir during nebulization and optimizes the volume of the aerosol mixing chamber to minimize freshly generated aerosol inter-droplet collision, impaction of aerosol to the aerosol mixing chamber wall, droplet growth and/or condensation during exhalation, prior to inhalation, or during inhalation. The larger aerosol mixing chamber volume also allows the aerosol to accumulate during the exhalation phase. Despite venting producing a larger generated aerosol droplet population mean compared to the non-vented aerosol generator, The combined effect of the invention increases device output rate of respirable aerosol droplets, increases pirfenidone Cmax and AUC to improve treatment or prevention of various diseases, including disease associated with the lung, heart and kidney, including fibrosis, inflammatory conditions and transplant rejection.

公开(公告)号：WO2022066802A1

公开(公告)日：2022-03-31

申请号：PCT/US2021/051598

申请日：2021-09-22

Applicant: AVALYN PHARMA INC.

Inventor： SURBER, Mark William ,  PHAM, Stephen

IPC: A61M11/00 ,  A61M16/00 ,  A61M15/00 ,  A61K9/00

Abstract: Disclosed herein is a nebulizer comprising of a medicine cup reservoir containing an aqueous pirfenidone solution a medicine cup reservoir cap, an aerosol generator, an aerosol mixing chamber to which freshly generated aerosol resides until inhaled, a one-way inhalation valve, a mouthpiece and a one-way exhalation valve. The invention allows atmospheric pressure to be maintained inside the medicine cup reservoir during nebulization and optimizes the volume of the aerosol mixing chamber to minimize freshly generated aerosol inter-droplet collision, impaction of aerosol to the aerosol mixing chamber wall, droplet growth and/or condensation during exhalation, prior to inhalation, or during inhalation. The larger aerosol mixing chamber volume also allows the aerosol to accumulate during the exhalation phase. Despite venting producing a larger generated aerosol droplet population mean compared to the non-vented aerosol generator, The combined effect of the invention increases device output rate of respirable aerosol droplets, increases pirfenidone Cmax and AUC to improve treatment or prevention of various diseases, including disease associated with the lung, heart and kidney, including fibrosis, inflammatory conditions and transplant rejection.

公开(公告)号：WO2018213209A1

公开(公告)日：2018-11-22

申请号：PCT/US2018/032615

申请日：2018-05-14

Applicant: NAVIGATE CARDIAC STRUCTURES, INC.

Inventor： QUIJANO, Rodolfo ,  BERTWELL, Ryan

IPC: A61F2/02 ,  A61F2/04 ,  A61F2/07 ,  A61F2/24 ,  A61F2/91

Abstract: This invention discloses a valved stent for implantation at a dysfunctional or diseased atrioventricular valvular annulus. The valved stent is expandable from a collapsed shape to an expanded shape for minimally invasive delivery and has a low profile at the atrial or superior aspect to achieve improved hemodynamics and offers the capability to fabricate replacement valves having large diameters, The invention also includes a delivery apparatus uniquely designed for implantation of the valved stent and offering the potential for controlled and precise placement of the valved stent at the atrioventricular annulus. The invention also includes methods for use of the above devices and for treating diseased atrioventricular valves.